摘要: The pharmacological use of plasminogen activators is associated with symptomatic improvement in patients coronary artery thrombosis, peripheral arterial occlusions, and thrombosis the venous system. Based on prospective angiographic studies planned programs (1, 2, 3, 4, 5), thrombolysis only approved treatment acute ischemic stroke (6, 7, 8) under limited circumstances. Currently, recombinant tissue activator (rt-PA) licensed United States several other countries for within 3 h onset (6).